FM
MXCT icon

Freemont Management’s MaxCyte MXCT Stock Holding History

Freemont Management’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,500
Closed -$68K – 116
2022
Q3 		$68K Buy
10,500
+771
+8% +$4.3K 0.01% 127
2022
Q2 		$46K Hold
9,729
– – 0.01% 131
2022
Q1 		$68K Buy
+9,729
New +$66.4K 0.01% 132

Other funds holding MXCT

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $159M AUM 139.66% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Freemont Management's MXCT Position: Q4 2022 in Review

Freemont Management sold out of MaxCyte (MXCT) in Q4 2022, closing a stake of 10,500 shares — an estimated $68K sold.

Freemont Management first reported a position in MXCT in Q1 2022 and held it in 3 quarters. The position peaked at $68K in Q3 2022. 104 funds tracked by Wall St. Rank hold MXCT as of Q4 2022.

  • Freemont Management reported no remaining MaxCyte position as of Q4 2022 after selling out during the quarter.
  • Freemont Management sold 10,500 MaxCyte shares in Q4 2022, an estimated $68K.
  • Freemont Management first reported a position in MaxCyte in Q1 2022 and held it in 3 quarters.
  • Freemont Management's MaxCyte position peaked at $68K in Q3 2022.
  • 104 funds tracked by Wall St. Rank held MaxCyte as of Q4 2022.

Based on Freemont Management's 13F filing for Q4 2022, filed 10 Feb 2023.